Data spans prostate and bladder cancer applications, including real-world outcomes and clinical trial results for genomic testing platform.
Veracyte Inc is presenting more than 15 abstracts featuring its urology testing portfolio at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place Feb 26-28 in San Francisco.
The studies span prostate and bladder cancers, showcasing real-world data for Decipher Prostate and clinical trial insights including the company’s upcoming TrueMRD Muscle-Invasive Bladder Cancer (MIBC) test. The research demonstrates how Veracyte’s genomic tests are being integrated into clinical decision-making and treatment studies.
“The breadth of data at ASCO GU shows how our Veracyte Diagnostics Platform is driving meaningful insight across multiple urologic cancers,” says Elai Davicioni, PhD, Veracyte’s medical director of urology, in a release. “In bladder cancer, Decipher is increasingly being integrated into studies that aim to help guide treatment decisions.”
Key Bladder Cancer Studies
One highlighted study is SURE-02, a phase II trial examining how genomic subtyping with the Decipher Bladder test can inform treatment approaches in bladder cancer. The trial tested neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by response-adapted bladder sparing and adjuvant pembrolizumab.
“The findings underscore the importance of molecular subtyping in muscle-invasive bladder cancer and support the integration of genomic classifiers, such as the Decipher Bladder test, into clinical trial design, for the first time suggesting a biologically informed strategy for the use of anti-TROP2 ADCs,” says Andrea Necchi, MD, principal investigator of the SURE-02 trial and presenter from IRCCS San Raffaele Hospital.
Other bladder cancer presentations include data from the HCRN GU 20-444 response-guided bladder-sparing trial featuring Veracyte’s upcoming TrueMRD MIBC test, and results from NURE-combo and BLASST-01 trials using Decipher Bladder.
Prostate Cancer Research
The company will also present several studies connecting real-world data and outcomes to the Decipher Prostate test and the Decipher Genomics Research for Intelligent Discovery platform. These include research on prostate cancer in patients with HIV infection and analysis of androgen production genes in localized prostate cancer.
The Decipher Prostate test is a 22-gene classifier developed using RNA whole-transcriptome analysis and machine learning that helps inform treatment decisions by providing risk assessment for developing metastasis. The test has achieved “Level 1B” evidence status and inclusion in National Comprehensive Cancer Network Guidelines for prostate cancer.
The Decipher Bladder test is a 219-gene classifier that classifies bladder tumors into five molecular subtypes to help physicians understand potential benefits from neoadjuvant chemotherapy and likelihood of non-organ-confined disease at surgery.
Veracyte’s TrueMRD testing approach uses artificial intelligence and whole-genome sequencing to create a molecular profile for each patient’s tumor and track cancer recurrence over time from blood samples. The company plans to begin offering its first TrueMRD test for muscle-invasive bladder cancer in the first half of 2026.
Photo caption: Decipher prostate cancer test
File photo / Veracyte
